{'fraction_non_alphanumeric': 0.035381750465549346, 'fraction_numerical': 0.0186219739292365, 'mean_word_length': 5.635802469135802, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
HICJ Hypermethylation Is a Late Event in Hematopoietic Neoplasmst

Hid, a candidate tumor suppressor gene on l7p13.3, is hypermethy lated and silenced in a large number of solid tumors. To determine Its potential role in leukemias, we studied its methylatlon status in normal and neoplastic hematopoletic eels. We found HICJ to he unmethylated in peripheral blood cells, bone marrow eels, and CD34+ cells. HICJ was rarely methylated in newly diagnosed acute myelogenous leukemias (10%) but was relatively frequently methylated in newly diagnosed non Hodgkin's lymphoma (25%), acute lymphocytic leukemia (ALL; 53%), and chronic-phasechronicmyelogenousleukemia(50%).By contrast, HICJ was hypennethylated in 100% of recurrent ALL and 100% of blast crisis chronic myelogenous leukemia. In two patients with ALL for whom paired diagnosis/relapse samples were available, HICI was unmethylated at diagnosis but was highly methylated at relapse after a chemotherapy induced complete remission. HICI methylation, therefore, seems to be a progression event in hematopoletic neoplasms.